Results 61 to 70 of about 15,395 (120)

Online tutorial on survival analysis for biomarker discovery. [PDF]

PLoS Comput Biol
Kokošar J, Praznik E, Špendl M, Moreno NP, Newell A, Shaulsky G, Zupan B.   +6 more
europepmc   +1 more source

Factors associated with clinical outcomes of breast cancer based on glucose metabolic activity of subcutaneous adipose tissue. [PDF]

Front Oncol
Mai J, Wu H, Wu W, Zhou J, Wu Y, Duan X, Wu R, Hu Y, Zhen Z, Huang B.   +9 more
europepmc   +1 more source

Permutation Tests Based on the Copula-Graphic Estimator and Their Use for Survival Tree Construction. [PDF]

Stat Med
Baur P, Pauly M, Emura T.
europepmc   +1 more source

A permutation test for a weighted Kaplan-Meier estimator with application to the nutritional prevention of cancer trial. [PDF]

Contemp Clin Trials, 2007
Frankel PH, Reid ME, Marshall JR.
europepmc   +1 more source

Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia. [PDF]

Blood Adv
Schroeder JC, Schwartz F, Metzdorf J, Barensteiner N, Mix L, Necke LM, Fehn A, Riedel A, Jentzsch L, Faustmann P, Vogel W, Bethge WA, Schroeder T, Lengerke C.   +13 more
europepmc   +1 more source

Comment on "Average Hazard as Harmonic Mean" by Chiba (2025). [PDF]

Pharm Stat
Uno H, Tian L, Horiguchi M, Hattori S.
europepmc   +1 more source

A comparison of Kaplan-Meier-based inverse probability of censoring weighted regression methods. [PDF]

Lifetime Data Anal
Overgaard M.
europepmc   +1 more source

Risk functions with outcome measurement error. [PDF]

Biostatistics
Edwards JK, Cole SR, Zivich PN, Ackerman B, Napravnik S, Henderson H, Lash T, Shook-Sa BE.   +7 more
europepmc   +1 more source

Structural and Non-Structural Deterioration After Biological Aortic Valve Replacement: Long-Term Outcomes of 918 High-Risk Patients. [PDF]

J Cardiovasc Dev Dis
Hlavička J, Landgraf J, Winter A, von Zeppelin M, Ilgin Y, Salem R, Hecker F, Walther T, Holubec T.   +8 more
europepmc   +1 more source

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials. [PDF]

NPJ Precis Oncol
Nichetti F, Hüllein J, du Rusquec P, Pleasance E, Chen L, Mock A, Horak P, Ambrosini P, Rota S, Niger M, Agnelli L, Tinè G, Edelmann D, Le Tourneau C, Laskin J, Pruneri G, Wang C, Hübschmann D, de Braud F, Fröhling S, Mariani L.   +20 more
europepmc   +1 more source